問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Show-Chwan Memorial Hospital (在職)

Division of Hematology & Oncology

Chang Bing Show Chwan Memorial Hospital

Division of Hematology & Oncology

Chang Bing Show Chwan Memorial Hospital

更新時間：2023-09-19

劉大智Liu, Ta-Chih
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉大智

Chang Bing Show Chwan Memorial Hospital

Division of Hematology & Oncology

List

9Cases

2026-05-01 - 2034-12-31

Phase III

Active
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

  • Condition/Disease

    Myelodysplastic Syndrome、 Anemia

  • Test Drug

    皮下注射劑

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2025-03-01 - 2029-12-31

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2023-05-10 - 2025-04-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2024-10-01 - 2035-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2025-06-01 - 2027-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-02 - 2027-11-03

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-04-30 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-01-17 - 2032-06-14

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-12-26 - 2028-10-20

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB